LIB 01
Alternative Names: DIC-2024; LIB-01; Libiguin®; Libiguin® DIC2024Latest Information Update: 10 Apr 2024
At a glance
- Originator Uppsala University
- Developer Dicot
- Class Erectile dysfunction therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Erectile dysfunction
- Preclinical Premature ejaculation
Most Recent Events
- 10 Apr 2024 Dicot AB completes a phase I trial in Erectile dysfunction (In volunteers) in Sweden (PO) (NCT06324006)
- 05 Apr 2024 Pharmacokinetics and adverse event data from a phase I trial in Erectile dysfunction released by Dicot
- 25 Oct 2023 Phase-I clinical trials in Erectile dysfunction (In volunteers) in Sweden (PO)